Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory agent (IMiD) presented as an oral tablet for oral use. It is indicated for certain blood cancers and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in hematologic malignancies where it modulates abnormal cell growth and immune response. - Multiple myeloma: improves progression‑free survival and overall response rates when combined with other agents. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and corrects cytopenias. - Mantle cell lymphoma: contributes to disease control as part of combination therapy.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Diarrhea: mild to moderate loose stools. - Rash: skin erythema or pruritus. - Constipation: reduced bowel movements. - Nausea: occasional upset stomach. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil counts increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient history and monitor laboratory parameters. - Pregnancy risk: contraindicated in pregnancy due to teratogenicity; ensure effective contraception. - Thrombosis risk: assess for clotting disorders and consider prophylactic anticoagulation. - Renal function: adjust monitoring for patients with impaired kidney function. - Hepatic function: monitor liver enzymes regularly. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with thrombosis prophylaxis.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. - P-glycoprotein inhibitors (e.g., verapamil): could increase plasma levels. - Vaccines: live vaccines should be avoided during treatment.